lung cancer

Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday. What Happened Genprex, which uses a non-viral, proprietary platform to deliver tumor suppressor genes to cancer cells, said the FDA has granted Fast Track...

AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company. What Happened The U.K.-based pharma giant said its Phase 3 POSEIDON trial produced positive results.  The study is evaluating AstraZeneca's Imfinzi — an anti-PD-L1...

The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-...

Analysts at Barclays no longer hold a bullish view on Merck & Co., Inc. (NYSE: MRK) due to a now diminished potential for its biggest value driver, Keytruda. The firm's Geoff Meacham downgraded Merck's stock rating from Overweight to Equal Weight with a price target slashed from $72 to $62....

Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2...

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...

Shares of OncoCyte Corp (NYSE: OCX) were highly volatile Monday and Tuesday in reaction to the company presenting positive lung cancer blood test data to the American Thoracic Society. Keay Nakae of Chardan maintains a Buy rating on OncoCyte's stock with a price target raised from $5.50 to $7.50,...

Shares of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) soared higher by more than 60 percent early Thursday morning after the molecular profiling company confirmed regulatory approval for its products in Europe. HTG Molecular announced that it has obtained CE marking in the European Union for its...

Lung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...

VolitionRX Ltd (NYSE: VNRX) stirred up some interest in the biotech community with blood tests that can predict colon cancer. What this means is that patients may no longer have to subject themselves to an invasive colonoscopy. In an exclusive interview with Benzinga, CEO Cameron Reynolds...